The 2025-2027 approval helps French innovators access Intravacc’s vaccine development, analytical development and cGMP manufacturing services ...

The 2025-2027 approval helps French innovators access Intravacc's vaccine development, analytical development and cGMP manufacturing services French Ministry approval recognizes Intravacc as a private ...

Eli Lilly has agreed to acquire three privately-held developers of vaccines for infectious diseases for a combined up-to-$3.83 billion cash, in deals intended to expand the acquisitive pharma giant’s ...

Marine organisms have evolved a remarkable arsenal of host-defense peptides under conditions of extreme variability and ...

Biocytogen today announced the launch of RenSuper Workstation, a next-generation AI-powered antibody discovery platform providing off-the-shelf access to a large-scale, experimentally validated ...

India, May 24 -- A current rash of contagious (communicable) disease outbreaks worldwide is a healthcare nightmare that the ...

A Japanese-led research team has developed AUN, a groundbreaking immune-independent bacterial cancer therapy that uses two harmonized bacteria to destroy tumors even in patients with weakened immune ...

Late-breaking Phase 3 SUCCESSOR-2 study results highlight potential of mezigdomide, a novel CELMoD from the Company’s targeted protein degradation platform, in relapsed or refractory multiple ...

EMERALD-3: Phase III trial of IMFINZI ® (durvalumab) in combination with IMJUDO ® (tremelimumab-actl), with or without lenvatinib, and transarterial chemoembolization (TACE) in patients with ...

Eli Lilly and Company is spending up to $3.8 billion to buy three vaccine makers, supercharging its push into the immunology space. Lilly has agreed to acquire Curevo Vaccine, owner of a midstage ...

Mark Gurarie is a writer covering health topics, technology, music, books, and culture. He also teaches health science and research writing at George Washington University's School of Medical and ...